BTI Share Price

Open 1.22 Change Price %
High 1.23 1 Day -0.01 -0.83
Low 1.19 1 Week -0.06 -4.80
Close 1.19 1 Month -0.16 -11.85
Volume 33000 1 Year -0.10 -7.75
52 Week High 2.05
52 Week Low 0.95
BTI Important Levels
Resistance 2 1.23
Resistance 1 1.21
Pivot 1.20
Support 1 1.17
Support 2 1.15
CVE Canada Most Active Stocks
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
PRY 0.02 0.00%
MVN 0.10 42.86%
MVN 0.10 42.86%
COD 0.07 0.00%
COD 0.07 0.00%
COD 0.07 0.00%
DVN 0.17 0.00%
More..
CVE Canada Top Gainers Stocks
CUI 0.02 100.00%
CUI 0.02 100.00%
GRI 0.02 100.00%
GRI 0.02 100.00%
GTC 0.02 100.00%
GTC 0.02 100.00%
BVQ 0.02 100.00%
CZH 0.02 100.00%
CZH 0.02 100.00%
CZH 0.02 100.00%
More..
CVE Canada Top Losers Stocks
FEM 0.02 -50.00%
FEM 0.02 -50.00%
FEM 0.02 -50.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
BMA 0.06 -40.00%
SB 0.03 -40.00%
SB 0.03 -40.00%
More..

biOasis Technologies Inc (CVE: BTI)

BTI Technical Analysis 5
As on 7th Dec 2016 BTI Share Price closed @ 1.19 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.37 & Strong Sell for SHORT-TERM with Stoploss of 1.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
BTI Target for December
1st Target up-side 1.43
2nd Target up-side 1.55
3rd Target up-side 1.66
1st Target down-side 1.11
2nd Target down-side 0.99
3rd Target down-side 0.88
BTI Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.bioasis.ca
BTI Address
BTI
1385 West 8th Avenue
Suite 600
Vancouver, BC V6H 3V9
Canada
Phone: 778-383-3280
Fax: 604-215-0091
Interactive Technical Analysis Chart biOasis Technologies Inc ( BTI CVE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on biOasis Technologies Inc
BTI Business Profile
biOasis Technologies Inc., an early stage biopharmaceutical company, engages in the research, development, and commercialization of technologies and products for the diagnosis and treatment of central nervous system diseases and disorders. The company develops Transcend program, a protein vector, which is a proprietary carrier for the transport of therapeutic agents across the blood brain barrier for treatment of a range of neurological, oncological, and infectious disease applications; and Cognitest, a proprietary in vitro diagnostic assay for Alzheimer’s disease. It has a collaborative research agreement with the University of British Columbia to assist the company in development of an enzyme linked immunosorbent assay to detect levels of p97 in blood for the purpose of evaluating the correlation between p97 and Alzheimer’s disease. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.